The Foundation on Which We Are Built

We are powered by a seasoned management team with a proven track record in developing the world's leading oncology drugs.

Daniel Gold, PHD

President & Chief Executive Officer

Dan took the helm in April 2010. Under his leadership, the company has established its headquarters in the U.S., assembled a proven oncology drug development team, developed a pipeline of clinical-stage assets and established a strong financial position.

Robert Mass, MD

Chief Medical Officer

After more than 10 years as a practicing hematologist and medical oncologist, Bob joined the clinical development organization at Genentech, where he served as clinical science leader for blockbuster oncology drugs Herceptin®, Tarceva® and Avastin®.

Brian Drazba

Chief Financial Officer

In April 2017, we appointed Brian Drazba as our new Chief Financial Officer. Brian is an accomplished financial executive with more than 25 years of financial management experience in the healthcare industry, most recently as Chief Financial Officer of Heron Therapeutics, a commercial-stage biotechnology company. Brian succeeds Thomas Zech, who retired after a distinguished career spanning four decades.

David Urso, JD

Senior Vice President, Corporate Development & General Counsel

Prior to joining us in March 2014, David co-founded Tioga Pharmaceuticals, a privately held drug development company. As a Principal at Forward Ventures, he was responsible for identifying and developing life science venture capital investments.

Karen Potts, PhD

Senior Vice President, Regulatory Affairs

Karen’s distinguished career spans both the biotechnology and pharmaceutical industries, where she has led global regulatory teams to successfully facilitate the development, approval and life cycle management of therapeutic drugs and biologics.

Richard Ghalie, MD

Senior Vice President, Clinical Development

Richard is a hematologist and oncologist with more than 20 years of drug development experience. He has served as the medical lead of teams that resulted in the approval of four new indications.

Ofir Moreno, PhD

Vice President, Research & Development

An organic chemist by training, Ofir joined us in September 2010 and has played a leading role in advancing three of the company's pre-clinical drug candidates through IND-enabling studies and into clinical trials, including ME-401 and ME-344.